Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells

Biomaterials

Volumn 35, Issue 3, 2014, Pages 1096-1108

  Ke, Xi Yu ^a,b   Lin Ng, Victor Wee ^a   Gao, Shu Jun ^a   Tong, Yen Wah ^c   Hedrick, James L ^d   Yang, Yi Yan ^a  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d IBM ALMADEN RESEARCH CENTER   (United States)

Author keywords

Cancer stem cells; Co delivery; Doxorubicin; Polycarbonates; Polymeric micelles; Thioridazine

Indexed keywords

CANCER STEM CELLS; CO DELIVERIES; DOXORUBICIN; POLYMERIC MICELLE; THIORIDAZINE;

BIOLOGICAL MATERIALS; BLOCK COPOLYMERS; CELL CULTURE; DISEASE CONTROL; DRUG PRODUCTS; MICELLES; POLYCARBONATES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYMERS; STEM CELLS; UREA;

DISEASES;

COPOLYMER; DOXORUBICIN; MACROGOL; POLYCARBONATE; POLYMER; THIORIDAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER STEM CELL; CELL GROWTH; CELL KILLING; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; HUMAN CELL; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

MUS MUSCULUS;

CANCER STEM CELLS; CO-DELIVERY; DOXORUBICIN; POLYCARBONATES; POLYMERIC MICELLES; THIORIDAZINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DOPAMINE ANTAGONISTS; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NEOPLASTIC STEM CELLS; POLYCARBOXYLATE CEMENT; POLYETHYLENE GLYCOLS; THIORIDAZINE;

EID: 84887626984     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.10.049     Document Type: Article

References (35)

1. Vargo-Gogola T., Rosen J.M. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7:659-672.
2. Parkin D.M., Fernández L.M. Use of statistics to assess the global burden of breast cancer. Breast J 2006, 12:S70-S80.
3. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22.
4. Economopoulou P., Kaklamani V.G., Siziopikou K. The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist 2012, 17:1394-1401.
5. Vermeulen L., de Sousa e Melo F., Richel D.J., Medema J.P. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012, 13:e83-e89.
6. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
7. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
8. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. JNatl Cancer Inst 2008, 100:672-679.
9. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
10. Frosina G. DNA repair in normal and cancer stem cells, with special reference to the central nervous system. Curr Med Chem 2009, 16:854-866.
11. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012, 109:2784-2789.
12. Hirsch H.A., Iliopoulos D., Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A 2013, 110:972-977.
13. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
14. Liu Y., Lu W.L., Guo J., Du J., Li T., Wu J.W., et al. Apotential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. JControl Release 2008, 129:18-25.
15. Li R.J., Ying X., Zhang Y., Ju R.J., Wang X.X., Yao H.J., et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. JControl Release 2011, 149:281-291.
16. Sachlos E., Risueño R.M., Laronde S., Shapovalova Z., Lee J.H., Russell J., et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012, 149:1284-1297.
17. Carlo R.D., Muccioli G., Bellussi G., Portaleone P., Ghi P., Racca S., et al. Steroid, prolactin, and dopamine receptors in normal and pathologic breast tissue. Ann N Y Acad Sci 1986, 464:559-562.
18. Baker P.B., Merigian K.S., Roberts J.R., Pesce A.J., Kaplan L.A., Rashkin M.C. Hyperthermia, hypertension, hypertonia, and coma in a massive thioridazine overdose. Am J Emerg Med 1988, 6:346-349.
19. Buckley N.A., Whyte I.M., Dawson A.H. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. JToxicol Clin Toxicol 1995, 33:199-204.
20. Prahalathan C., Selvakumar E., Varalakshmi P. Lipoic acid modulates adriamycin-induced testicular toxicity. Reprod Toxicol 2006, 21:54-59.
21. Broxterman H.J., Gotink K.J., Verheul H.M. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 2009, 12:114-126.
22. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.B. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008, 108:241-250.
23. Plummer R., Wilson R.H., Calvert H., Boddy A.V., Griffin M., Sludden J., et al. Aphase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer 2011, 104:593-598.
24. Wiradharma N., Zhang Y., Venkataraman S., Hedrick J.L., Yang Y.Y. Self-assembled polymer nanostructures for delivery of anticancer therapeutics. Nano Today 2009, 4:302-317.
25. Croy S.R., Kwon G.S. Polymeric micelles for drug delivery. Curr Pharm Des 2006, 12:4669-4684.
26. Yang C., Tan J.P.K., Cheng W., Attia A.B.E., Ting C.T.Y., Nelson A., et al. Supramolecular nanostructures designed for high cargo loading capacity and kinetic stability. Nano Today 2010, 5:515-523.
27. Yang C., Attia A.B., Tan J.P., Ke X., Gao S., Hedrick J.L., et al. The role of non-covalent interactions in anticancer drug loading and kinetic stability of polymeric micelles. Biomaterials 2012, 33:2971-2979.
28. Attia A.B., Yang C., Tan J.P., Gao S., Williams D.F., Hedrick J.L., et al. The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles. Biomaterials 2013, 34:3132-3140.
29. Pratt R.C., Lohmeijer B.G.G., Long D.A., Lundberg P.N.P., Dove A.P., Li H., et al. Exploration, optimization, and application of supramolecular thiourea-amine catalysts for the synthesis of lactide (co)polymers. Macromolecules 2006, 39:7863-7871.
30. Golebiewska A., Brons N.H., Bjerkvig R., Niclou S.P. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011, 8:136-147.
31. Zhu K.J., Hendren R.W., Jensen K., Pitt C.G. Synthesis, properties, and biodegradation of poly (1, 3-trimethylene carbonate). Macromolecules 1991, 24:1736-1740.
32. Liu S.Q., Tong Y.W., Yang Y.Y. Incorporation and invitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N, N-dimethylacrylamide)-b-poly(D, L-lactide-co-glycolide) with varying compositions. Biomaterials 2005, 26:5064-5074.
33. McAuliffe S.M., Morgan S.L., Wyant G.A., Tran L.T., Muto K.W., Chen Y.S., et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 2012, 109:E2939-E2948.
34. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69:7507-7511.
35. Iliopoulos D., Hirsch H.A., Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011, 71:3196-3201.